Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Summary
A study of ASP2151 in subjects with recurrent outbreaks of genital herpes.
Eligible Conditions
- Genital Herpes
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2015 Phase 3 trial • 468 Patients • NCT019592957%
Alpha 1 microglobulin increased
5%
Nasopharyngitis
4%
Fibrin degradation products increased
4%
Genital herpes
4%
Oral herpes
3%
Beta-N-acetyl-D-glucosaminidase increased
1%
Electrocardiogram QT prolonged
100%
80%
60%
40%
20%
0%
Study treatment Arm
ASP2151
ASP2151 Placebo
Trial Design
6Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: 6Experimental Treatment1 Intervention
Dosing regimen 4
Group II: 5Experimental Treatment1 Intervention
Dosing regimen 3
Group III: 4Experimental Treatment1 Intervention
Dosing regimen 2
Group IV: 3Experimental Treatment1 Intervention
Dosing regimen 1
Group V: 1Active Control1 Intervention
Oral administration of active comparator
Group VI: 2Placebo Group1 Intervention
Oral administration of placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Amenamevir
Not yet FDA approved
Find a Location
Who is running the clinical trial?
Astellas Pharma IncLead Sponsor
695 Previous Clinical Trials
232,613 Total Patients Enrolled
Use Central ContactStudy DirectorAstellas Pharma US, Inc.
182 Previous Clinical Trials
51,809 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger